This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winer, K. K. Articles by Cutler, G. B. Search for Related Content PubMed PubMed Citation Articles by Winer, K. K. Articles by Cutler, G. B., Jr.

A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1–34 in Treatment of Hypoparathyroidism

Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland 20892-1862

Address all correspondence and requests for reprints to: Karen K. Winer, National Institute of Child Health and Human Development/Developmental Endocrinology Branch, Building 10, Room 10N262, 10 Center Drive, MSC 1862, National Institutes of Health, Bethesda, Maryland 20892-1862.

Once-daily sc injection of PTH 1–34 can normalize mean serum and urine calcium levels in patients with hypoparathyroidism; however, once-daily PTH has diminishing effects on serum calcium after 12 h, such that serum calcium levels fall below the normal range in some patients. Once-daily PTH also causes a marked increase in bone turnover, with persistent increases in markers of bone formation and resorption. To test the hypothesis that a twice-daily PTH regimen can produce more physiological control than a once-daily regimen, we performed a randomized cross-over trial, lasting 28 weeks, in 17 adult subjects with hypoparathyroidism. Each 14-week study arm was divided into a 2-week inpatient dose-adjustment phase and a 12-week outpatient phase. The PTH dose (given sc once daily at 0900 h or twice daily with one dose at 0900 h and the other at 2100 h) was adjusted to maintain both serum and urine calcium within, or close to, the normal range.

During the second half of the day (12–24 h), twice-daily PTH increased serum calcium and magnesium levels more effectively than once-daily PTH. In patients with calcium receptor mutations (CaR), once-daily PTH normalized urine calcium, provided that serum calcium was maintained at levels below normal range. However, twice-daily PTH treatment produced higher mean serum calcium in patients with CaR with no significant rise in urine calcium excretion, and with no significant differences in either serum or urine calcium levels between CaR and patients with acquired or idiopathic hypoparathyroidism. Thus, treatment with twice-daily PTH is the better regimen for patients with CaR to overcome their tendency to hypercalciuria while producing near-normal levels of serum calcium. The total daily PTH dose was markedly reduced with the twice-daily regimen (twice daily 46 ± 52 vs. once daily 97 ± 60 µg/day, P < 0.001). We conclude that a twice-daily PTH regimen provides effective treatment of hypoparathyroidism and reduces the variation in serum calcium levels at a lower total daily PTH dose.

This article has been cited by other articles:

				M. Puig-Domingo, G. Diaz, J. Nicolau, C. Fernandez, S. Rueda, and I. Halperin Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide Eur. J. Endocrinol., November 1, 2008; 159(5): 653 - 657. [Abstract] [Full Text] [PDF]

				M. J. Horwitz and A. F. Stewart Hypoparathyroidism: Is It Time for Replacement Therapy? J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3307 - 3309. [Full Text] [PDF]

				S. D. Mittelman, G. N. Hendy, R. A. Fefferman, L. Canaff, I. Mosesova, D. E. C. Cole, L. Burkett, and M. E. Geffner A Hypocalcemic Child with a Novel Activating Mutation of the Calcium-Sensing Receptor Gene: Successful Treatment with Recombinant Human Parathyroid Hormone J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2474 - 2479. [Abstract] [Full Text] [PDF]

				K. K. Winer, C. W. Ko, J. C. Reynolds, K. Dowdy, M. Keil, D. Peterson, L. H. Gerber, C. McGarvey, and G. B. Cutler Jr. Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1-34) Versus Calcitriol and Calcium J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4214 - 4220. [Abstract] [Full Text] [PDF]

				K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, and K. Fujieda Hydrochlorothiazide Effectively Reduces Urinary Calcium Excretion in Two Japanese Patients with Gain-of-Function Mutations of the Calcium-Sensing Receptor Gene J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3068 - 3073. [Abstract] [Full Text] [PDF]

				R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763. [Abstract] [Full Text] [PDF]